NextCure has fallen below Nasdaq’s minimum stockholders’ equity requirement, putting its continued listing in question if the shortfall is not addressed. The company expects its proposed merger with Avere Therapeutics to close before Nasdaq’s deadline and believes the deal would restore compliance, but the merger still requires stockholder approval and other closing conditions.
- Equity shortfall: NextCure reported stockholders’ equity of $5.503 million at September 30, below Nasdaq’s $10 million minimum. As of November 16, it also did not meet Nasdaq’s alternative standards based on market value or assets and revenue.
- Deadline to address the issue: NextCure has until January 4, 2027, to submit a plan to regain compliance. If the merger does not close before then, the company intends to submit a plan.
- Merger timing: The proposed merger with Avere is expected to close in mid-December 2026, ahead of the compliance-plan deadline. That timing depends on NextCure stockholder approval and other customary closing conditions.
- Trading status: The Nasdaq notice does not immediately affect the listing or trading of NextCure common stock, which remains on the Nasdaq Global Select Market, subject to the company meeting other listing requirements.
What changes for investors: The merger is NextCure’s expected route to restoring the required equity level, but that outcome depends on the transaction closing in time. Until then, the stock remains listed; the company has said it will pursue a compliance plan if the merger is delayed or does not close before the deadline.
